• Definium Therapeutics granted options to purchase 269,800 common shares to ten newly hired non-executive employees.
• The grants, effective November 9, 2026, were approved November 6, 2026, under the 2026 Inducement Plan.
• Options vest over four years, with 25% vesting on the first grant anniversary.
• The remaining 75% vests in substantially equal monthly increments over the next three years, subject to each employee's continued employment.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Definium Therapeutics Inc. published the original content used to generate this news brief via Business Wire (Ref. ID: 20261106394941) on November 09, 2026, and is solely responsible for the information contained therein.